Periodic Reporting for period 1 - MICAL (Structural and mechanistic basis of MICAL regulation)
Période du rapport: 2021-02-01 au 2023-01-31
These findings provide a launchpad for addressing more complex questions, such as what controls axon length and directionality, how axons change shape, and how we can promote regrowth in damaged or diseased axons.
I believe that the project has achieved its main objectives and significantly improved my experience and competence. Furthermore, this project exceeded my expectations in terms of its impact on my career, as I successfully established a new Laboratory of Structural Neurobiology and secured my position as a Junior Group Leader.
We also tried to understand how MICAL works with other proteins called plexin receptors. Unfortunately, we were not able to detect any binding between them. So, we tried using another protein called Rab8, which we found in previous studies. Testing Rab8 and MICAL together, we observed direct binding. However, we have not yet determined the structure of the complex due to difficulties with plexin. Nevertheless, this project is ongoing, and we expect to determine the structure of the complex soon.
Another goal of the project was personal growth, and I believe this goal was fully addressed. In particular, I significantly improved my leadership and management skills by attending four workshops focused on project management. My leadership skills were further developed by supervising two undergraduate students.
The findings of this research will be published soon, and we expect to submit two manuscript by the end of this year. I presented the results through conferences and a number of invited talks. Our research was also popularized through newspaper interviews.
Furthermore, the MICAL family poses a series of interconnected questions that are of fundamental importance for our understanding of a broad range of biomedically relevant activities. Our findings provide insight into how to modulate MICAL interactions to switch between active and inhibited states, which could pave the way to treating MICAL-related diseases. Recent studies on MICALs have revealed a number of disease-causing mutations, and our determination of the overall hMICAL1 structure can provide informative delineation of the effects of these mutations on the mechanisms of particular diseases, particularly autosomal-dominant lateral temporal epilepsy. I am excited to map these mutations onto the structure of hMICAL1 in the future, perform in-depth structure-based analysis, and investigate the possible impact of these mutations on the protein structure and hence its function.